Successful Personalization of Propylene Glycol Free Melphalan (PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Using Pharmacokinetic (PK)-Directed Dosing

Body surface area-based dosing of melphalan prior to AHCT for MM and AL patients causes inter-patient variability in exposure measured by area under the curve (AUC). Higher AUC is associated with increased toxicity, but prolonged survival (Shaw et al., BBMT 2012). Using Evomela (PGF-MEL, Acrotech Biopharma LLC), a more stable and possibly less toxic intravenous formulation of melphalan, we examined the feasibility of PK-directed dosing to individualize and optimize therapy.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Gunjan L. Shah, Andrew Lin, Alyssa Kamrowski, Caroline A. Carino, Ryan Schofield, Sean M. Devlin, Valkal Bhatt, Anthony J. Proli, David J. Chung, Parastoo B. Dahi, Oscar Boutros Lahoud, Michael Scordo, Dean Carlow, Sergio A. Giralt, Heather J. Landau Tags: 224 Source Type: research